Low-Dose r-ATG vs Basiliximab in Low-Risk Living-Donor Kidney Transplantation: Outcomes in Acute Rejection, Graft Function, and Infections

21 October 2025 : Original article

Nam Ho

^{ABDEF 1}, Thu Thi Nguyen^{BCDF 1}, Nam Van Do^{BCD 1}, Chi Tam Nguyen

^{BEF 1}, Su Xuan Hoang^{DEF 2}, Khanh Vo Ngoc Hoang^{BEF 3}, Trung Dinh Ngo^{ABDEF 1*}

DOI: 10.12659/AOT.949942

Ann Transplant 2025; 30:e949942

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 4 Kidney function after transplantation (eGFR, mean [mL/min/1.73 m2]).

e-GFR, mean (mL/min/1.73 m2)	Total (n=150)	Low-dose r-ATG (n=37)	Basiliximab (n=113)
1 month	74.87	75.4	74.7
3 months	71.78	70.80	72.10
6 months	74.20	77.97	73.29
12 months	74.49	73.24	74.90
18 months	75.35	71.45	76.67
24 months	76.35	74.08	76.74
30 months	76.27	76.58	76.16
36 months	73.72	74.63	73.0
GFR – glomerular filtration rate.

Back to the Article